169 related articles for article (PubMed ID: 23407483)
1. Sunitinib for the treatment of metastatic paraganglioma and vasoactive intestinal polypeptide-producing tumor (VIPoma).
Bourcier ME; Vinik AI
Pancreas; 2013 Mar; 42(2):348-52. PubMed ID: 23407483
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib achieved fast and sustained control of VIPoma symptoms.
de Mestier L; Walter T; Brixi H; Lombard-Bohas C; Cadiot G
Eur J Endocrinol; 2015 Jan; 172(1):K1-3. PubMed ID: 25305306
[TBL] [Abstract][Full Text] [Related]
3. Activity of sunitinib in patients with advanced neuroendocrine tumors.
Kulke MH; Lenz HJ; Meropol NJ; Posey J; Ryan DP; Picus J; Bergsland E; Stuart K; Tye L; Huang X; Li JZ; Baum CM; Fuchs CS
J Clin Oncol; 2008 Jul; 26(20):3403-10. PubMed ID: 18612155
[TBL] [Abstract][Full Text] [Related]
4. Metastatic paraganglioma and treatment with sunitinib: a case report.
Cirillo F
Tumori; 2010; 96(6):1022-7. PubMed ID: 21388069
[TBL] [Abstract][Full Text] [Related]
5. Transient sunitinib-induced coma in a patient with fibromyxoid sarcoma.
Arnaud L; Schartz NE; Bousquet G; Sarandi F; Verola O; Madelaine I; Kerob D; Lebbe C
J Clin Oncol; 2008 Mar; 26(9):1569-71. PubMed ID: 18349416
[No Abstract] [Full Text] [Related]
6. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
7. Sporadic pancreatic vasoactive intestinal peptide-producing tumor (VIPoma) in a 47-year-old male.
Abu-Zaid A; Azzam A; Abudan Z; Algouhi A; Almana H; Amin T
Hematol Oncol Stem Cell Ther; 2014 Sep; 7(3):109-15. PubMed ID: 24785507
[TBL] [Abstract][Full Text] [Related]
8. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.
Eichelberg C; Heuer R; Chun FK; Hinrichs K; Zacharias M; Huland H; Heinzer H
Eur Urol; 2008 Dec; 54(6):1373-8. PubMed ID: 18692304
[TBL] [Abstract][Full Text] [Related]
9. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V
Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
[TBL] [Abstract][Full Text] [Related]
10. Metastatic pancreatic VIPoma: deteriorating clinical course and successful treatment by liver transplantation.
Hengst K; Nashan B; Avenhaus W; Ullerich H; Schlitt HJ; Flemming P; Pichlmayr R; Domschke W
Z Gastroenterol; 1998 Mar; 36(3):239-45. PubMed ID: 9577908
[TBL] [Abstract][Full Text] [Related]
11. Metastatic hepatic epithelioid hemangio-endothelioma: long-term response to sunitinib malate.
Saada E; Saint Paul MC; Gugenheim J; Follana P; François E
Oncol Res Treat; 2014; 37(3):124-6. PubMed ID: 24685916
[TBL] [Abstract][Full Text] [Related]
12. [Long-term therapy of a metastasizing pancreatic vipoma using the somatostatin derivative octreotide].
Flückiger A; Schlup P
Schweiz Med Wochenschr; 1992 Aug; 122(33):1221-3. PubMed ID: 1326786
[TBL] [Abstract][Full Text] [Related]
13. Treatment of metastatic Vipoma by liver transplantation.
Bramley PN; Lodge JP; Losowsky MS; Giles GR
Clin Transplant; 1990 Oct; 4(5 part 1):276-8; discussion 279. PubMed ID: 10150088
[TBL] [Abstract][Full Text] [Related]
14. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
[TBL] [Abstract][Full Text] [Related]
15. Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey.
Masini C; Sabbatini R; Porta C; Procopio G; Di Lorenzo G; Onofri A; Buti S; Iacovelli R; Invernizzi R; Moscetti L; Aste MG; Pagano M; Grosso F; Lucia Manenti A; Ortega C; Cosmai L; Del Giovane C; Conte PF
BJU Int; 2012 Sep; 110(5):692-8. PubMed ID: 22364110
[TBL] [Abstract][Full Text] [Related]
16. Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma.
Ayllon J; Beuselinck B; Morel A; Barrascout E; Medioni J; Scotte F; Oudard S
Cancer Invest; 2011 May; 29(4):282-5. PubMed ID: 21469976
[TBL] [Abstract][Full Text] [Related]
17. Response and safety of sunitinib in a heavily pre-treated metastatic non-small cell lung carcinoma patient.
Tassi R; Muto A; Rangan S; Vannini A; Politi L; Neri B
Anticancer Res; 2010 Dec; 30(12):5169-73. PubMed ID: 21187507
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of efficacy and safety of sunitinib regimen in 22 patients with metastatic renal cell carcinoma: at least 12-month follow-up.
Zhang CJ; Zhao PJ; Li XS; Zhao J; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; He ZS; Jin J; Zhou LQ
Chin Med J (Engl); 2013; 126(15):2826-9. PubMed ID: 23924450
[TBL] [Abstract][Full Text] [Related]
20. Metastatic vipoma arising from colonic primary tumour.
Bradley C; Haddock G; Pickard RG; Rankin EM
Eur J Surg Oncol; 1989 Aug; 15(4):386-9. PubMed ID: 2547666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
